2026-05-12T22:53:21Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/151032024-11-28T17:26:00Zcom_20.500.12105_19604com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19605col_20.500.12105_16960col_20.500.12105_16967col_20.500.12105_16970col_20.500.12105_16977col_20.500.12105_16981

00925njm 22002777a 4500 dc Rossello, Xavier author Raposeiras-Roubin, Sergio author Latini, Roberto author Dominguez-Rodriguez, Alberto author Barrabés, José A author Sánchez, Pedro L author Anguita, Manuel author Fernández-Vázquez, Felipe author Pascual-Figal, Domingo A author De la Torre Hernandez, José M author Ferraro, Stefano author Vetrano, Alfredo author Pérez-Rivera, José A author Prada-Delgado, Oscar author Escalera, Noemí author Staszewsky, Lidia author Pizarro, Gonzalo author Agüero, Jaume author Pocock, Stuart author Ottani, Filippo author Fuster, Valentin author Ibáñez, Borja author 2022-05 Aims: There is a lack of evidence regarding the benefits of β-blocker treatment after invasively managed acute myocardial infarction (MI) without reduced left ventricular ejection fraction (LVEF). Methods and results: The tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT) trial is a pragmatic, controlled, prospective, randomized, open-label blinded endpoint (PROBE design) clinical trial testing the benefits of β-blocker maintenance therapy in patients discharged after MI with or without ST-segment elevation. Patients eligible for participation are those managed invasively during index hospitalization (coronary angiography), with LVEF >40%, and no history of heart failure (HF). At discharge, patients will be randomized 1:1 to β-blocker therapy (agent and dose according to treating physician) or no β-blocker therapy. The primary endpoint is a composite of all-cause death, non-fatal reinfarction, or HF hospitalization over a median follow-up period of 2.75 years (minimum 2 years, maximum 3 years). Key secondary endpoints include the incidence of the individual components of the primary composite endpoint, the incidence of cardiac death, and incidence of malignant ventricular arrhythmias or resuscitated cardiac arrest. The primary endpoint will be analysed according to the intention-to-treat principle. Conclusion: The REBOOT trial will provide robust evidence to guide the prescription of β-blockers to patients discharged after MI without reduced LVEF. Eur Heart J Cardiovasc Pharmacother . 2022 May 5;8(3):291-301. 10.1093/ehjcvp/pvab060 2055-6845 European heart journal. Cardiovascular pharmacotherapy https://hdl.handle.net/20.500.13003/20159 34351426 L2018179365 2-s2.0-85129998561 http://hdl.handle.net/20.500.12105/15103 756395700001 Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)